Search

Your search keyword '"van Gelder, Michel"' showing total 236 results
Start Over Author "van Gelder, Michel" Search Limiters Available in Library Collection
236 results on '"van Gelder, Michel"'

1. Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL

Author

Beckers, M. M. J., Bekker, A., Bellido, M., de Boer, F., Broers, R., Chamuleau, M., Croockewit, A. J., Dompeling, E. C., Eefting, M., van Gelder, M., Hoogendoorn, M., Houtenbos, I., Doorduijn, J. K., Droogendijk, J., van der Griend, R., de Heer, K., Henkens, C. M. A., Idink, C. A. M., Issa, D. E., van Kampen, R., Kater, A. P., Kersting, S., van der Klift, M., Laterveer, L., Levenga, H., Levin, M-D., Mous, R., Nijland, M., Nijziel, M., van Norden, Y., Posthuma, E. F. M., te Raa, G. D., Raymakers, R. A. P., Regelink, J. C., Sandberg, Y., Schaafsma, M. R., Silbermann, M. H., van der Spek, A. C., van der Straaten, H. M., Tanis, B., Terpstra, W. E., Tick, L. W., Tonino, S. H., Veelken, J. H., Velders, G. A., Vlasveld, L., Visser, H. P. J., Vos, J. M. I., Wittebol, S., van Zaanen, H. C. T., van der Straten, Lina, Stege, Claudia A. M., Kersting, Sabina, Nasserinejad, Kazem, Dubois, Julie, Dobber, Johan A., Mellink, Clemens H. M., van der Kevie-Kersemaekers, Anne-Marie F., Evers, Ludo M., de Boer, Fransien, Koene, Harry R., Schreurs, John, van der Klift, Marjolein, Velders, Gerjo A., van der Spek, Ellen, van der Straaten, Hanneke M., Hoogendoorn, Mels, van Gelder, Michel, Posthuma, Eduardus F. M., Visser, Hein P. J., Houtenbos, Ilse, Idink, Cecile A. M., Issa, Djamila E., Dompeling, Ellen C., van Zaanen, Henk C. T., Veelken, J. Hendrik, Levenga, Henriette, Tick, Lidwine W., Terpstra, Wim E., Tonino, Sanne H., Westerweel, Peter E., Langerak, Anton W., Kater, Arnon P., and Levin, Mark-David

Published
2023
Full Text
View/download PDF

2. Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi‐state modeling

Author

Hermans, Sjoerd J. F., primary, van Norden, Yvette, additional, Versluis, Jurjen, additional, Rijneveld, Anita W., additional, van der Holt, Bronno, additional, de Weerdt, Okke, additional, Biemond, Bart J., additional, van de Loosdrecht, Arjan A., additional, van der Wagen, Lotte E., additional, Bellido, Mar, additional, van Gelder, Michel, additional, van der Velden, Walter J. F. M., additional, Selleslag, Dominik, additional, van Lammeren‐Venema, Daniëlle, additional, van der Velden, Vincent H. J., additional, de Wreede, Liesbeth C., additional, Postmus, Douwe, additional, Pignatti, Francesco, additional, and Cornelissen, Jan J., additional

Published
2024
Full Text
View/download PDF

4. Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL

Author

Antic, Darko, Milic, Natasa, Chatzikonstantinou, Thomas, Scarfò, Lydia, Otasevic, Vladimir, Rajovic, Nina, Allsup, David, Alonso Cabrero, Alejandro, Andres, Martin, Baile Gonzales, Monica, Capasso, Antonella, Collado, Rosa, Cordoba, Raul, Cuéllar-García, Carolina, Correa, Juan Gonzalo, De Paoli, Lorenzo, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Dimou, Maria, Doubek, Michael, Efstathopoulou, Maria, El-Ashwah, Shaimaa, Enrico, Alicia, Espinet, Blanca, Farina, Lucia, Ferrari, Angela, Foglietta, Myriam, Lopez-Garcia, Alberto, García-Marco, José A., García-Serra, Rocío, Gentile, Massimo, Gimeno, Eva, da Silva, Maria Gomes, Gutwein, Odit, Hakobyan, Yervand K., Herishanu, Yair, Hernández-Rivas, José Ángel, Herold, Tobias, Itchaki, Gilad, Jaksic, Ozren, Janssens, Ann, Kalashnikova, Olga B., Kalicińska, Elżbieta, Kater, Arnon P., Kersting, Sabina, Koren-Michowitz, Maya, Labrador, Jorge, Lad, Deepesh, Laurenti, Luca, Fresa, Alberto, Levin, Mark-David, Mayor Bastida, Carlota, Malerba, Lara, Marasca, Roberto, Marchetti, Monia, Marquet, Juan, Mihaljevic, Biljana, Milosevic, Ivana, Mirás, Fatima, Morawska, Marta, Motta, Marina, Munir, Talha, Murru, Roberta, Nunes, Raquel, Olivieri, Jacopo, Pavlovsky, Miguel Arturo, Piskunova, Inga, Popov, Viola Maria, Quaglia, Francesca Maria, Quaresmini, Giulia, Reda, Gianluigi, Rigolin, Gian Matteo, Shrestha, Amit, Šimkovič, Martin, Smirnova, Svetlana, Špaček, Martin, Sportoletti, Paolo, Stanca, Oana, Stavroyianni, Niki, Te Raa, Doreen, Tomic, Kristina, Tonino, Sanne, Trentin, Livio, Van Der Spek, Ellen, van Gelder, Michel, Varettoni, Marzia, Visentin, Andrea, Vitale, Candida, Vukovic, Vojin, Wasik-Szczepanek, Ewa, Wróbel, Tomasz, Segundo, Lucrecia Yáñez San, Yassin, Mohamed, Coscia, Marta, Rambaldi, Alessandro, Montserrat, Emili, Foà, Robin, Cuneo, Antonio, Carrier, Marc, Ghia, Paolo, and Stamatopoulos, Kostas

Published
2022
Full Text
View/download PDF

5. Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial

Author

Rijneveld, Anita W., van der Holt, Bronno, de Weerdt, Okke, Biemond, Bart J., van de Loosdrecht, Arjen A., van der Wagen, Lotte E., Bellido, Mar, van Gelder, Michel, van der Velden, Walter J.F.M., Selleslag, Dominik, van Lammeren-Venema, Daniëlle, Halkes, Constantijn J.M., Fijnheer, Rob, Havelange, Violaine, van Sluis, Geerte L., Legdeur, Marie-Cecile, Deeren, Dries, Gadisseur, Alain, Sinnige, Harm A.M., Breems, Dimitri A., Jaspers, Aurélie, Legrand, Ollivier, Terpstra, Wim E., Boersma, Rinske S., Mazure, Dominiek, Triffet, Agnes, Tick, Lidwine W., Beel, Karolien, Maertens, Johan A., Beverloo, H. Berna, Bakkus, Marleen, Homburg, Christa H.E., de Haas, Valerie, van der Velden, Vincent H.J., and Cornelissen, Jan J.

Published
2022
Full Text
View/download PDF

6. Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study

Author

Saberi Hosnijeh, Fatemeh, van der Straten, Lina, Kater, Arnon P., van Oers, Marinus H.J., Posthuma, Ward F.M., Chamuleau, Martine E.D., Bellido, Mar, Doorduijn, Jeanette K., van Gelder, Michel, Hoogendoorn, Mels, de Boer, Fransien, te Raa, G. Doreen, Kerst, J. Martijn, Marijt, Erik W.A., Raymakers, Reinier A.P., Koene, Harry R., Schaafsma, Martijn R., Dobber, Johan A., Tonino, Sanne H., Kersting, Sabina S., Langerak, Anton W., and Levin, Mark-David

Published
2020
Full Text
View/download PDF

7. The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL

Author

Visentin, Andrea, primary, Chatzikonstantinou, Thomas, additional, Scarfò, Lydia, additional, Kapetanakis, Anargyros, additional, Demosthenous, Christos, additional, Karakatsoulis, Georgios, additional, Minga, Eva, additional, Chamou, Dimitra, additional, Allsup, David, additional, Cabrero, Alejandro Alonso, additional, Andres, Martin, additional, Antic, Darko, additional, Baile, Mónica, additional, Baliakas, Panagiotis, additional, Besikli‐Dimou, Sotiria, additional, Bron, Dominique, additional, Chatzileontiadou, Sofia, additional, Cordoba, Raul, additional, Correa, Juan‐Gonzalo, additional, Cuéllar‐García, Carolina, additional, De Paoli, Lorenzo, additional, De Paolis, Maria Rosaria, additional, Delgado, Julio, additional, Dimou, Maria, additional, Donaldson, David, additional, Catherwood, Mark, additional, Doubek, Michael, additional, Efstathopoulou, Maria, additional, Eichhorst, Barbara, additional, Elashwah, Salma, additional, Enrico, Alicia, additional, Espinet, Blanca, additional, Farina, Lucia, additional, Ferrari, Angela, additional, Foglietta, Myriam, additional, Frederiksen, Henrik, additional, Fürstenau, Moritz, additional, García‐Marco, José A., additional, García‐Serra, Rocío, additional, Collado, Rosa, additional, Gentile, Massimo, additional, Gimeno, Eva, additional, Glenthøj, Andreas, additional, da Silva, Maria Gomes, additional, Hakobyan, Yervand K., additional, Herishanu, Yair, additional, Hernández‐Rivas, José Ángel, additional, Herold, Tobias, additional, Innocenti, Idanna, additional, Itchaki, Gilad, additional, Jaksic, Ozren, additional, Janssens, Ann, additional, Kalashnikova, Оlga B., additional, Kalicińska, Elżbieta, additional, Kater, Arnon P., additional, Kersting, Sabina, additional, Labrador, Jorge, additional, Lad, Deepesh, additional, Laurenti, Luca, additional, Levin, Mark‐David, additional, Lista, Enrico, additional, Lopez‐Garcia, Alberto, additional, Malerba, Lara, additional, Marasca, Roberto, additional, Marchetti, Monia, additional, Marquet, Juan, additional, Mattsson, Mattias, additional, Mauro, Francesca R., additional, Morawska, Marta, additional, Motta, Marina, additional, Munir, Talha, additional, Murru, Roberta, additional, Niemann, Carsten U., additional, Rodrigues, Raquel Nunes, additional, Olivieri, Jacopo, additional, Orsucci, Lorella, additional, Papaioannou, Maria, additional, Pavlovsky, Miguel Arturo, additional, Piskunova, Inga, additional, Popov, Viola Maria, additional, Quaglia, Francesca Maria, additional, Quaresmini, Giulia, additional, Qvist, Kristian, additional, Rigolin, Gian Matteo, additional, Ruchlemer, Rosa, additional, Šimkovič, Martin, additional, Špaček, Martin, additional, Sportoletti, Paolo, additional, Stanca, Oana, additional, Tadmor, Tamar, additional, Capasso, Antonella, additional, Del Poeta, Giovanni, additional, Gutwein, Odit, additional, Karlsson, Linda Katharina, additional, Milosevic, Ivana, additional, Mirás, Fatima, additional, Reda, Gianluigi, additional, Saghumyan, Gevorg, additional, Shrestha, Amit, additional, Te Raa, Doreen, additional, Tonino, Sanne H., additional, Van Der Spek, Ellen, additional, van Gelder, Michel, additional, van Kampen, Roel, additional, Wasik‐Szczepanek, Ewa, additional, Wróbel, Tomasz, additional, Segundo, Lucrecia Yáñez San, additional, Yassin, Mohamed, additional, Pocali, Barbara, additional, Vandenberghe, Elisabeth, additional, Iyengar, Sunil, additional, Varettoni, Marzia, additional, Vitale, Candida, additional, Coscia, Marta, additional, Rambaldi, Alessandro, additional, Montserrat, Emili, additional, Cuneo, Antonio, additional, Stavroyianni, Niki, additional, Trentin, Livio, additional, Stamatopoulos, Kostas, additional, and Ghia, Paolo, additional

Published
2023
Full Text
View/download PDF

8. Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL

Author

van der Straten, Lina, primary, Stege, Claudia A. M., additional, Kersting, Sabina, additional, Nasserinejad, Kazem, additional, Dubois, Julie, additional, Dobber, Johan A., additional, Mellink, Clemens H. M., additional, van der Kevie-Kersemaekers, Anne-Marie F., additional, Evers, Ludo M., additional, de Boer, Fransien, additional, Koene, Harry R., additional, Schreurs, John, additional, van der Klift, Marjolein, additional, Velders, Gerjo A., additional, van der Spek, Ellen, additional, van der Straaten, Hanneke M., additional, Hoogendoorn, Mels, additional, van Gelder, Michel, additional, Posthuma, Eduardus F. M., additional, Visser, Hein P. J., additional, Houtenbos, Ilse, additional, Idink, Cecile A. M., additional, Issa, Djamila E., additional, Dompeling, Ellen C., additional, van Zaanen, Henk C. T., additional, Veelken, J. Hendrik, additional, Levenga, Henriette, additional, Tick, Lidwine W., additional, Terpstra, Wim E., additional, Tonino, Sanne H., additional, Westerweel, Peter E., additional, Langerak, Anton W., additional, Kater, Arnon P., additional, and Levin, Mark-David, additional

Published
2023
Full Text
View/download PDF

10. Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia

Author

Schetelig, Johannes, de Wreede, Liesbeth C., van Gelder, Michel, Koster, Linda, Finke, Jürgen, Niederwieser, Dietger, Beelen, Dietrich, Mufti, G. J., Platzbecker, Uwe, Ganser, Arnold, Heidenreich, Silke, Maertens, Johan, Socié, Gerard, Brecht, Arne, Stelljes, Matthias, Kobbe, Guido, Volin, Liisa, Nagler, Arnon, Vitek, Antonin, Luft, Thomas, Ljungman, Per, Yakoub-Agha, Ibrahim, Robin, Marie, and Kröger, Nicolaus

Published
2019
Full Text
View/download PDF

11. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel

Author

de Witte, Theo, Bowen, David, Robin, Marie, Malcovati, Luca, Niederwieser, Dietger, Yakoub-Agha, Ibrahim, Mufti, Ghulam J., Fenaux, Pierre, Sanz, Guillermo, Martino, Rodrigo, Alessandrino, Emilio Paolo, Onida, Francesco, Symeonidis, Argiris, Passweg, Jakob, Kobbe, Guido, Ganser, Arnold, Platzbecker, Uwe, Finke, Jürgen, van Gelder, Michel, van de Loosdrecht, Arjan A., Ljungman, Per, Stauder, Reinhard, Volin, Liisa, Deeg, H.Joachim, Cutler, Corey, Saber, Wael, Champlin, Richard, Giralt, Sergio, Anasetti, Claudio, and Kröger, Nicolaus

Published
2017
Full Text
View/download PDF

12. Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, and the Societé Française de Greffe de Moelle et Therapie Cellulaire

Author

Xavier, Erick, Cornillon, Jérôme, Ruggeri, Annalisa, Chevallier, Patrice, Cornelissen, Jan J., Andersen, Niels S., Maillard, Natacha, Nguyen, Stephanie, Blaise, Didier, Deconinck, Eric, Veelken, Hendrik, Milpied, Noel, Van Gelder, Michel, Peffault de Latour, Regis, Gluckman, Eliane, Kröger, Nicolaus, Schetelig, Johannes, and Rocha, Vanderson

Published
2015
Full Text
View/download PDF

13. Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience

Author

Chihara, Dai, primary, Gras, Luuk, additional, Zinger, Nienke, additional, Kröger, Nicolaus, additional, Mayer, Jiri, additional, Passweg, Jakob, additional, De Latour, Régis Peffault, additional, Byrne, Jenny, additional, Krüger, William, additional, Bohn, Jan-Paul, additional, Platzbecker, Uwe, additional, Blau, Igor Wolfgang, additional, Bonifazi, Francesca, additional, Helbig, Grzegorz, additional, McDonald, Andrew, additional, Mistrik, Martin, additional, Mohty, Mohamad, additional, Ram, Ron, additional, Sanz, Jaime, additional, Llamas, Carlos Vallejo, additional, Kreitman, Robert J., additional, Hayden, Patrick J., additional, McLornan, Donal, additional, Tournilhac, Olivier, additional, Van Gelder, Michel, additional, and Yakoub-Agha, Ibrahim, additional

Published
2022
Full Text
View/download PDF

14. Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study

Author

Niederwieser, Dietger, primary, Hasenclever, Dirk, additional, Berdel, Wolfgang E., additional, Biemond, Bart J., additional, Al-Ali, Haifa Kathrin, additional, Chalandon, Yves, additional, Van Gelder, Michel, additional, Junghanss, Christian, additional, Gahrton, Goesta, additional, Haenel, Mathias, additional, Hehlmann, Rüdiger, additional, Heinicke, Thomas, additional, Hochhaus, Andreas, additional, Iacobelli, Simona, additional, Kooy, Rien van Marwijk, additional, Kröger, Nicolaus, additional, Janssen, Jeroen J.W.M., additional, Jentzsch, Madlen, additional, Breywisch, Frank, additional, Mohty, Mohamad, additional, Masouridi-Levrat, Stavroula, additional, Ossenkoppele, Gert, additional, Passweg, Jakob, additional, Pönisch, Wolfram, additional, Schetelig, Johannes, additional, Schliemann, Christoph, additional, Schwind, Sebastian, additional, Stelljes, Matthias, additional, Valk, Peter JM, additional, Lowenberg, Bob, additional, and Cornelissen, Jan J., additional

Published
2022
Full Text
View/download PDF

15. First-Line Treatment and Outcome of T-Cell Prolymphocytic Leukemia in the Netherlands; A Nationwide Population-Based Study

Author

Brink, Mirian, primary, van der Spek, Arie C., additional, de Heer, Koen, additional, Kersting, Sabina, additional, Tick, Lidwine W., additional, van der Straaten, Hanneke M., additional, Mous, Rogier, additional, Levin, Mark-David, additional, Raa, Doreen te, additional, van Gelder, Michel, additional, Doorduijn, Jeanette K., additional, Kater, Arnon P., additional, Huls, Gerwin, additional, and Bellido, Mar, additional

Published
2022
Full Text
View/download PDF

16. The HOVON 100 Study in Adult Acute Lymphoblastic Leukemia Re-Analysed By Multi-State Modeling: Benefits and Risks of Clofarabine

Author

Hermans, Sjoerd J.F., primary, Norden, Yvette, additional, Versluis, Jurjen, additional, Rijneveld, Anita W., additional, De Weerdt, Okke, additional, Biemond, Bart J., additional, van de Loosdrecht, Arjan A., additional, Van der Wagen, Lotte E., additional, Bellido, Mar, additional, Van Gelder, Michel, additional, Van der Velden, Walter J.F.M., additional, Selleslag, Dominik, additional, van Lammeren, Danielle, additional, van der Velden, Vincent H.J., additional, de Wreede, Liesbeth C., additional, Postmus, Douwe, additional, Pignatti, Francesco, additional, and Cornelissen, Jan J., additional

Published
2022
Full Text
View/download PDF

17. Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study

Author

Visentin, Andrea, primary, Scarfò, Lydia, additional, Chatzikonstantinou, Thomas, additional, Kapetanakis, Anargyros, additional, Demosthenous, Christos, additional, Karakatsoulis, Georgios, additional, Andres, Martin, additional, Antic, Darko, additional, Allsup, David, additional, Baile, Mónica, additional, Bron, Dominique, additional, Capasso, Antonella, additional, Catherwood, Mark, additional, Collado, Rosa, additional, Cordoba, Raul, additional, Cuéllar-García, Carolina, additional, Delgado, Julio, additional, Dimou, Maria, additional, Doubek, Michael, additional, De Paoli, Lorenzo, additional, De Paolis, Maria Rosaria, additional, Del Poeta, Giovanni, additional, Efstathopoulou, Maria, additional, Shimaa, El-Ashwah, additional, Enrico, Alicia, additional, Farina, Lucia, additional, Ferrari, Angela, additional, Foglietta, Myriam, additional, Furstenau, Moritz, additional, Garcia-Marco, Jose A., additional, Gentile, Massimo, additional, Gimeno, Eva, additional, Maria, Gomes da Silva, additional, Gutwein, Odit, additional, Hakobyan, Yervand, additional, Herishanu, Yair, additional, Hernandez, jose Angel, additional, Herold, Tobias, additional, Iyengar, Sunil, additional, Itchaki, Gilad, additional, Jaksic, Ozren, additional, Janssens, Ann, additional, Kalashnikova, Olga, additional, Kalicinska, Elzbieta, additional, Kater, Arnon P., additional, Kersting, Sabina, additional, Labrador, Jorge, additional, Lad, Deepesh, additional, Laurenti, Luca, additional, Levin, Mark-David, additional, Lista, Enrico, additional, Malerba, Lara, additional, Marasca, Roberto, additional, Marchetti, Monia, additional, Marquet Palomanes, Juan, additional, Mattsson, Mattias, additional, Mauro, Francesca Romana, additional, Mayor-Bastida, Carlota, additional, Morawska, Marta, additional, Motta, Marina, additional, Munir, Talha, additional, Murru, Roberta, additional, Milosevic, Ivana, additional, Miras Calvo, Fatima, additional, Niemann, Carsten Utoft, additional, Olivieri, Jacopo, additional, Orsucci, Lorella, additional, Papaioannou, Maria, additional, Pavlovsky, Miguel Arturo, additional, Piskunova, Inga S., additional, Pocali, Barbara, additional, Popov, Viola Maria, additional, Quaglia, Francesca Maria, additional, Quaresmini, Giulia, additional, Raa, Doreen te, additional, Reda, Gianluigi, additional, Rigolin, Gian Matteo, additional, Ruchlemer, Rosa, additional, Shrestha, Amit, additional, Šimkovič, Martin, additional, Špaček, Martin, additional, Sportoletti, Paolo, additional, Stanca Ciocan, Oana, additional, Tadmor, Tamar, additional, Vandenberghe, Elisabeth, additional, Varettoni, Marzia, additional, Vitale, Candida, additional, Van Der Spek, Ellen, additional, Van Gelder, Michel, additional, Wasik-Szczepanek, Ewa, additional, Yáñez, Lucrecia, additional, Yassin, Mohamed A, additional, Coscia, Marta, additional, Eichhorst, Barbara, additional, Rambaldi, Alessandro, additional, Stavroyianni, Niki, additional, Trentin, Livio, additional, Stamatopoulos, Kostas, additional, and Ghia, Paolo, additional

Published
2022
Full Text
View/download PDF

18. Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL

Author

Antic, Darko, primary, Milic, Natasa, additional, Chatzikonstantinou, Thomas, additional, Scarfò, Lydia, additional, Otasevic, Vladimir, additional, Rajovic, Nina, additional, Allsup, David, additional, Cabrero, Alejandro Alonso, additional, Andres, Martin, additional, Baile Gonzales, Monica, additional, Capasso, Antonella, additional, Collado, Rosa, additional, Cordoba, Raul, additional, Cuéllar-García, Carolina, additional, Correa, Juan Gonzalo, additional, De Paoli, Lorenzo, additional, De Paolis, Maria Rosaria, additional, Del Poeta, Giovanni, additional, Dimou, Maria, additional, Doubek, Michael, additional, Efstathopoulou, Maria, additional, El-Ashwah, Shaimaa, additional, Enrico, Alicia, additional, Espinet, Blanca, additional, Farina, Lucia, additional, Ferrari, Angela, additional, Foglietta, Myriam, additional, Lopez-Garcia, Alberto, additional, Garcia-Marco, Jose A., additional, García-Serra, Rocío, additional, Gentile, Massimo, additional, Gimeno, Eva, additional, Gomes da Silva, Maria, additional, Gutwein, Odit, additional, Hakobyan, Yervand, additional, Herishanu, Yair, additional, Hernández-Rivas, José Ángel, additional, Herold, Tobias, additional, Itchaki, Gilad, additional, Jaksic, Ozren, additional, Janssens, Ann, additional, Kalashnikova, Оlga B., additional, Kalicińska, Elżbieta, additional, Kater, Arnon P., additional, Kersting, Sabina, additional, Koren-Michowitz, Maya, additional, Gomez, Jorge Labrador, additional, Lad, Deepesh, additional, Laurenti, Luca, additional, Fresa, Alberto, additional, Levin, Mark-David, additional, Mayor Bastida, Carlota, additional, Malerba, Lara, additional, Marasca, Roberto, additional, Marchetti, Monia, additional, Marquet, Juan, additional, Mihaljevic, Biljana, additional, Milosevic, Ivana, additional, Mirás, Fatima, additional, Morawska, Marta, additional, Motta, Marina, additional, Munir, Talha, additional, Murru, Roberta, additional, Nunes, Raquel, additional, Olivieri, Jacopo, additional, Pavlovsky, Miguel Arturo, additional, Piskunova, Inga S., additional, Popov, Viola Maria, additional, Quaglia, Francesca Maria, additional, Quaresmini, Giulia, additional, Reda, Gianluigi, additional, Rigolin, Gian Matteo, additional, Shrestha, Amit, additional, Šimkovič, Martin, additional, Smirnova, Svetlana, additional, Špaček, Martin, additional, Sportoletti, Paolo, additional, Stanca, Oana, additional, Stavroyianni, Niki, additional, Te Raa, Doreen, additional, Tomic, Kristina, additional, Tonino, Sanne, additional, Trentin, Livio, additional, Van Der Spek, Ellen, additional, van Gelder, Michel, additional, Varettoni, Marzia, additional, Visentin, Andrea, additional, Vitale, Candida, additional, Vukovic, Vojin, additional, Wasik-Szczepanek, Ewa, additional, Wróbel, Tomasz, additional, Yanez San Segundo, Lucrecia, additional, Yassin, Mohamed A, additional, Coscia, Marta, additional, Rambaldi, Alessandro, additional, Montserrat, Emili, additional, Foà, Robin, additional, Cuneo, Antonio, additional, Carrier, Marc, additional, Ghia, Paolo, additional, and Stamatopoulos, Kostas, additional

Published
2022
Full Text
View/download PDF

19. Autologous Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia - a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Author

Drozd-Sokolowska, Joanna, primary, Gras, Luuk, additional, Zinger, Nienke, additional, Sierra, Jorge, additional, Rovira, Montserrat, additional, Salmenniemi, Urpu, additional, Zudaire, Teresa, additional, Bermúdez, Arancha, additional, Choi, Goda, additional, Collin, Matthew P., additional, Kaufmann, Martin, additional, Kozlowski, Piotr, additional, Poiré, Xavier, additional, Ribera, Josep-Maria, additional, Sampol, Antonia, additional, Wilson, Keith, additional, Duchosal, Michel A., additional, Gedde-Dahl, Tobias, additional, Deconinck, Eric, additional, Mirabile, Milena, additional, Raj, Kavita, additional, Van Gelder, Michel, additional, Tournilhac, Olivier, additional, McLornan, Donal P., additional, and Yakoub-Agha, Ibrahim, additional

Published
2022
Full Text
View/download PDF

21. Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study

Author

Niederwieser, Dietger, Hasenclever, Dirk, Berdel, Wolfgang E., Biemond, Bart J., Al-Ali, Haifa Kathrin, Chalandon, Yves, Van Gelder, Michel, Junghanss, Christian, Gahrton, Goesta, Haenel, Mathias, Hehlmann, Rüdiger, Heinicke, Thomas, Hochhaus, Andreas, Iacobelli, Simona, Kooy, Rien van Marwijk, Kröger, Nicolaus, Janssen, Jeroen J.W.M., Jentzsch, Madlen, Breywisch, Frank, Mohty, Mohamad, Masouridi-Levrat, Stavroula, Ossenkoppele, Gert, Passweg, Jakob, Pönisch, Wolfram, Schetelig, Johannes, Schliemann, Christoph, Schwind, Sebastian, Stelljes, Matthias, Valk, Peter JM, Lowenberg, Bob, and Cornelissen, Jan J.

Published
2022
Full Text
View/download PDF

24. Corrigendum: Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia

Author

Schetelig, Johannes, primary, Baldauf, Henning, additional, Koster, Linda, additional, Kuxhausen, Michelle, additional, Heidenreich, Falk, additional, de Wreede, Liesbeth C., additional, Spellman, Stephen, additional, van Gelder, Michel, additional, Bruno, Benedetto, additional, Onida, Francesco, additional, Lange, Vinzenz, additional, Massalski, Carolin, additional, Potter, Victoria, additional, Ljungman, Per, additional, Schaap, Nicolaas, additional, Hayden, Patrick, additional, Lee, Stephanie J., additional, Kröger, Nicolaus, additional, Hsu, Kathy, additional, Schmidt, Alexander H., additional, Yakoub-Agha, Ibrahim, additional, and Robin, Marie, additional

Published
2021
Full Text
View/download PDF

25. Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL

Author

Chatzikonstantinou, Thomas, primary, Scarfo, Lydia, additional, Demosthenous, Christos, additional, Kotaskova, Jana, additional, Iacoboni, Gloria, additional, Minga, Evangelia, additional, Chammou, Dimitra, additional, Karakatsoulis, Georgios, additional, Albi, Elisa, additional, Alcoceba, Miguel, additional, El-Ashwah, Shaimaa, additional, Bacchiarri, Francesca, additional, Khan, Mehreen Ali, additional, Aurran, Thérèse, additional, Calleja, Anne, additional, Cassin, Ramona, additional, Chatzileontiadou, Sofia, additional, Christian, Amy, additional, Claus, Rainer, additional, Collado, Rosa, additional, De Deus Santos, Marcos Daniel, additional, Davis, Zadie, additional, Dimou, Maria, additional, Donaldson, David, additional, Dos Santos, Gimena, additional, Dreta, Barbara, additional, Efstathopoulou, Maria, additional, Enrico, Alicia, additional, Fresa, Alberto, additional, Galimberti, Sara, additional, García-Serra, Rocío, additional, González-Gascón Y Marín, Isabel, additional, Gozzetti, Alessandro, additional, Guarente, Valerio, additional, Harrop, Sean, additional, Hatzimichael, Eleftheria, additional, Herishanu, Yair, additional, Inchiappa, Luca, additional, Iskas, Michalis, additional, Jaksic, Ozren, additional, Janssen, Susanne R., additional, Kalicinska, Elzbieta, additional, Karakus, Volkan, additional, Kater, Arnon P., additional, Kho, Bonnie, additional, Konstantinou, Iliana, additional, Longval, Thomas, additional, Koren-Michowitz, Maya, additional, Kotsianidis, Ioannis, additional, Kreitman, Robert J., additional, Nath, Uttam Kumar, additional, Labrador, Jorge, additional, Lad, Deepesh, additional, Laribi, Kamel, additional, Levy, Ilana, additional, Lopez-Garcia, Alberto, additional, Marquet Palomanes, Juan, additional, Maslejova, Stanislava, additional, Mayor-Bastida, Carlota, additional, Merabet, Fatiha, additional, Mihaljevic, Biljana, additional, Milosevic, Ivana, additional, Miras, Fatima, additional, Moia, Riccardo, additional, Morawska, Marta, additional, Navarro-Bailón, Almudena, additional, Oscier, David, additional, Olivieri, Jacopo, additional, Papajík, Tomáš, additional, Papaioannou, Maria, additional, Pierie, Cheyenne, additional, Puiggros, Anna, additional, Reda, Gianluigi, additional, Rigolin, Gian Matteo, additional, Ruchlemer, Rosa, additional, Schiattone, Luana, additional, Sevindik, Omur Gokmen, additional, Shen, Yandong, additional, Šimkovič, Martin, additional, Smirnova, Svetlana, additional, Soliman, Dina Sameh, additional, Špaček, Martin, additional, Schiwitza, Annett, additional, Tadmor, Tamar, additional, Tourjeman, Liat, additional, Tse, Eric, additional, Visentin, Andrea, additional, Tomic, Kristina, additional, Van Gelder, Michel, additional, Vassilakopoulos, Theodoros P., additional, Vitale, Candida, additional, Vrachiolias, George, additional, Vukovic, Vojin, additional, Xu, Zhenshu, additional, Yáñez, Lucrecia, additional, Yagci, Munci, additional, Yassin, Mohamed A, additional, Zuchnicka, Jana, additional, Angelopoulou, Maria K., additional, Antic, Darko, additional, Biderman, Bella V., additional, Catherwood, Mark, additional, Coscia, Marta, additional, Cuneo, Antonio, additional, Demirkan, Fatih, additional, Espinet, Blanca, additional, Gaidano, Gianluca, additional, Guièze, Romain, additional, Kalashnikova, Olga, additional, Laurenti, Luca, additional, Mulligan, Stephen, additional, Murru, Roberta, additional, Nikitin, Eugene A., additional, Panayiotidis, Panayiotis, additional, Pangalis, Gerasimos, additional, Panovska, Irina, additional, Popov, Viola Maria, additional, Pospíšilová, Šárka, additional, Smolej, Lukas, additional, Sportoletti, Paolo, additional, Stavroyianni, Niki, additional, Tam, Constantine S., additional, Trentin, Livio, additional, Trněný, Marek, additional, Bosch Albareda, Francesc, additional, Doubek, Michael, additional, Chatzidimitriou, Anastasia, additional, Ghia, Paolo, additional, and Stamatopoulos, Kostas, additional

Published
2021
Full Text
View/download PDF

26. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

Author

Chatzikonstantinou, Thomas Kapetanakis, Anargyros Scarfo, Lydia and Karakatsoulis, Georgios Allsup, David Alonso Cabrero, Alejandro Andres, Martin Antic, Darko Baile, Monica and Baliakas, Panagiotis Bron, Dominique Capasso, Antonella and Chatzileontiadou, Sofia Cordoba, Raul Correa, Juan-Gonzalo and Cuellar-Garcia, Carolina De Paoli, Lorenzo De Paolis, Maria Rosaria Del Poeta, Giovanni Demosthenous, Christos Dimou, Maria Donaldson, David Doubek, Michael Efstathopoulou, Maria and Eichhorst, Barbara El-Ashwah, Shaimaa Enrico, Alicia and Espinet, Blanca Farina, Lucia Ferrari, Angela Foglietta, Myriam Frederiksen, Henrik Furstenau, Moritz Garcia-Marco, Jose A. Garcia-Serra, Rocio Gentile, Massimo Gimeno, Eva and Glenthoj, Andreas da Silva, Maria Gomes Gutwein, Odit and Hakobyan, Yervand K. Herishanu, Yair Angel Hernandez-Rivas, Jose and Herold, Tobias Innocenti, Idanna Itchaki, Gilad Jaksic, Ozren Janssens, Ann Kalashnikova, Olga B. Kalicinska, Elzbieta Karlsson, Linda Katharina Kater, Arnon P. Kersting, Sabina Labrador, Jorge Lad, Deepesh Laurenti, Luca and Levin, Mark-David Lista, Enrico Lopez-Garcia, Alberto and Malerba, Lara Marasca, Roberto Marchetti, Monia Marquet, Juan Mattsson, Mattias Mauro, Francesca R. Milosevic, Ivana and Miras, Fatima Morawska, Marta Motta, Marina Munir, Talha and Murru, Roberta Niemann, Carsten U. Rodrigues, Raquel Nunes and Olivieri, Jacopo Orsucci, Lorella Papaioannou, Maria and Arturo Pavlovsky, Miguel Piskunova, Inga Popov, Viola Maria and Quaglia, Francesca Maria Quaresmini, Giulia Qvist, Kristian and Reda, Gianluigi Rigolin, Gian Matteo Ruchlemer, Rosa and Saghumyan, Gevorg Shrestha, Amit Simkovic, Martin Spacek, Martin Sportoletti, Paolo Stanca, Oana Stavroyianni, Niki and Tadmor, Tamar Te Raa, Doreen Tonino, Sanne H. Trentin, Livio Van der Spek, Ellen van Gelder, Michel van Kampen, Roel Varettoni, Marzia Visentin, Andrea Vitale, Candida and Wasik-Szczepanek, Ewa Wrobel, Tomasz Yanez San Segundo, Lucrecia and Yassin, Mohamed Coscia, Marta Rambaldi, Alessandro and Montserrat, Emili Foa, Robin Cuneo, Antonio Stamatopoulos, Kostas Ghia, Paolo

Abstract

Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p < 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41-0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02-1.04; HR = 1.79, 95% CI:1.04-3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated.

Published
2021

29. Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: Lessons from the randomized European Society for Blood and Marrow Transplantation-Intergroup study

Author

de Wreede, Liesbeth C., Watson, Maggie, van Os, Marleen, Milligan, Donald, van Gelder, Michel, Michallet, Mauricette, Dreger, Peter, Dearden, Claire E., Homewood, Janis, Dupuis, Jehan, Leporrier, Michel, Karas, Michal, Corront, Bernadette, Baerlocher, Gabriela M., Herr, Wolfgang, Choquet, Sylvain, Niederwieser, Dietger W., Sutton, Laurent, Kröger, Nicolaus, de Witte, Theo M., and Schetelig, Johannes

Published
2014
Full Text
View/download PDF

30. Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia

Author

Schetelig, Johannes, primary, Baldauf, Henning, additional, Koster, Linda, additional, Kuxhausen, Michelle, additional, Heidenreich, Falk, additional, de Wreede, Liesbeth C., additional, Spellman, Stephen, additional, van Gelder, Michel, additional, Bruno, Benedetto, additional, Onida, Francesco, additional, Lange, Vinzenz, additional, Massalski, Carolin, additional, Potter, Victoria, additional, Ljungman, Per, additional, Schaap, Nicolaas, additional, Hayden, Patrick, additional, Lee, Stephanie J., additional, Kröger, Nicolaus, additional, Hsu, Kathy, additional, Schmidt, Alexander H., additional, Yakoub-Agha, Ibrahim, additional, and Robin, Marie, additional

Published
2021
Full Text
View/download PDF

31. Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia

Author

Michallet, Mauricette, Dreger, Peter, Sobh, Mohamad, Koster, Linda, Hoek, Jennifer, Boumendil, Ariane, Scheid, Christof, Fox, Christopher P, Wulf, Gerald, Krüger, William, van Gelder, Michel, Corradini, Paolo, Russo, Domenico, Passweg, Jakob, Schoemans, Hélène, Bethge, Wolfgang, Schaap, Nicolaas, Cornelissen, Jan, Browne, Paul, Duraković, Nadira, Lutz, Muller, Montoto, Silvia, Kroger, Nicolaus, Schetelig, and Johannes

Subjects
surgical procedures, operative, immune system diseases, ibrutinib, salvage, bone marrow transplantation
Abstract

The purpose of our study is to provide information on safety and efficacy of ibrutinib as salvage treatment after allo-HSCT for CLL. A total of 56 patients were included, 36 (64%) males ; median age at transplantation was 48 years (range: 35–64) and the median number of treatment lines prior to transplantation was 3 (1–10). The median time between allo-HSCT and Ibrutinib was 30 months (range: 1–140). Overall, 40 (71%) patients responded to Ibrutinib ; 23 (41%) PR, and 17 (30%) CR. At time of ibrutinib initiation, ten patients had active chronic GVHD that resolved under Ibrutinib, whilst a single patient developed limited de novo chronic GVHD on Ibrutinib. Fourteen patients discontinued ibrutinib, four because of toxicity and ten because of disease progression. Overall, 14 patients progressed (median PFS = 24 months) among them 10 died. Two- year OS and PFS probabilities were 72% (95% CI: 52–84) and 50% (95% CI: 32– 66), respectively. Patients with late relapse after allo-HSCT (≥24 months) had a better PFS after ibrutinib. Our study shows that ibrutinib can be safely administered for CLL relapse after allo-HSCT, with comparable efficacy to non-transplanted patients with high-risk disease.

Published
2020

33. Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation

Author

Kalin, Burak, primary, van Norden, Yvette, additional, van Gelder, Michel, additional, Breems, Dimitri, additional, Maertens, Johan, additional, Jongen-Lavrencic, Mojca, additional, Broers, Annoek E. C., additional, Braakman, Eric, additional, Grob, Tim, additional, Zeijlemaker, Wendelien, additional, Ossenkoppele, Gert J., additional, Meijer, Ellen, additional, and Cornelissen, Jan J., additional

Published
2020
Full Text
View/download PDF

34. Autologous and Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Richter's Syndrome: A Large Series from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

Author

Tournilhac, Olivier, primary, Guièze, Romain, additional, Eikema, Dirk-Jan, additional, Zinger, Nienke, additional, Sengeloev, Henrik, additional, Passweg, Jakob R., additional, Nielsen, Bendt, additional, Poire, Xavier, additional, Byrne, Jenny, additional, Gramatzki, Martin, additional, Finke, Jürgen, additional, Cornelissen, Jan J, additional, Blaise, D, additional, Nikolousis, Emmanouil, additional, Chevallier, Patrice, additional, Van Gorkom, Gwendolyn, additional, Ringhoffer, Mark, additional, Mordini, Nicola, additional, de Wreede, Liesbeth C., additional, Hayden, Patrick John, additional, van Gelder, Michel, additional, and Yakoub-Agha, Ibrahim, additional

Published
2019
Full Text
View/download PDF

35. Time-Restricted Versus Standard Duration Immunosuppression after Allogeneic Hematopoietic Stem Cell Transplantation: Results from the Prospective Randomized Phase III HOVON-96 Trial

Author

De Jong, Cornelis N., primary, Meijer, Ellen, primary, Bakunina, Katerina, primary, Nur, Erfan, primary, van Marwijk Kooij, Marinus, primary, De Groot, Marco, primary, Van Gelder, Michel, primary, Maertens, Johan A., primary, Kuball, Jurgen H.E., primary, Deeren, Dries, primary, Van Der Holt, Bronno, primary, Cornelissen, Jan J, primary, and Broers, Annoek E.C., primary

Published
2019
Full Text
View/download PDF

36. Post-Transplantation Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplantation: Results of the Prospective Randomized HOVON-96 Trial in Recipients of Matched Related and Unrelated Donors

Author

De Jong, Cornelis N., primary, Meijer, Ellen, primary, Bakunina, Katerina, primary, Nur, Erfan, primary, van Marwijk Kooij, Marinus, primary, de Groot, Marco R., primary, van Gelder, Michel, primary, Maertens, Johan A., primary, Kuball, Jurgen H.E., primary, Deeren, Dries, primary, van der Holt, Bronno, primary, Cornelissen, Jan J, primary, and Broers, Annoek E.C., primary

Published
2019
Full Text
View/download PDF

37. Feasibility and efficacy of addition of individualized dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia

Author

Kater, Arnon P, van Oers, Marinus H J, van Norden, Yvette, van der Straten, Lina, Driessen, Julia, Posthuma, Ward F M, Schipperus, Martinus, Chamuleau, Martine E D, Nijland, Marcel, Doorduijn, Jeanette K, Van Gelder, Michel, Hoogendoorn, Mels, De Croon, Francien, Wittebol, Shulamiet, Kerst, J Martijn, Marijt, Erik W A, Raymakers, Reinier A P, Schaafsma, Martijn R, Dobber, Johan A, Kersting, Sabina A, Levin, Mark-David, and HOVON CLL study group

Subjects
Hematology
Abstract

Lenalidomide has been proven to be effective but with a distinct and difficult to manage toxicity profile in the context of chronic lymphocytic leukemia, potentially hampering combination treatment with this drug. We conducted a phase 1-2 study to evaluate the efficacy and safety of six cycles of chlorambucil (7 mg/m 2 daily), rituximab (375 mg/m 2 cycle 1 and 500 mg/m 2 cycles 2-6) and individually-dosed lenalidomide (escalated from 2.5 mg to 10 mg) (induction-I) in first-line treatment of patients with chronic lymphocytic leukemia unfit for treatment with fludarabine, cyclophosphamide and rituximab. This was followed by 6 months of 10 mg lenalidomide monotherapy (induction-II). Of 53 evaluable patients in phase 2 of the study, 47 (89%) completed induction-I and 36 (68%) completed induction-II. In an intention-to-treat analysis, the overall response rate was 83%. The median progression-free survival was 49 months, after a median follow-up time of 27 months. The 2-and 3-year progression-free survival rates were 58% and 54%, respectively. The corresponding rates for overall survival were 98% and 95%. No tumor lysis syndrome was observed, while tumor flair reaction occurred in five patients (9%, 1 grade 3). The most common hematologic toxicity was grade 3-4 neutropenia, which occurred in 73% of the patients. In conclusion, addition of lenalidomide to a chemotherapy backbone followed by a fixed duration of lenalidomide monotherapy resulted in high remission rates and progression-free survival rates, which seem comparable to those observed with novel drug combinations including novel CD20 monoclonal antibodies or kinase inhibitors. Although lenalidomide-specific toxicity remains a concern, an individualized dose-escalation schedule is feasible and results in an acceptable toxicity profile. EuraCT number: 2010-022294-34.

Published
2019

38. Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graftversus- host disease: A multicenter prospective study

Author

Servais, Sophie, Baron, Frédéric, Lechanteur, Chantal, Seidel, Laurence, Selleslag, Dominik, Maertens, Johan, Baudoux, Etienne, Zachee, Pierre, Van Gelder, Michel, Noens, Lucien, Kerre, Tessa, Lewalle, Philippe, Schroyens, Wilfried, Ory, Aurélie, and Beguin, Yves

Subjects
allogeneic hematopoietic cell transplantation, multipotent mesenchymal stromal cells, Corticosteroid-refractory acute graft-versus-host disease, corticosteroid-refractory acute graft-versus-host disease, Allogeneic hematopoietic cell transplantation, Multipotent mesenchymal stromal cells, Research Paper, Psychiatrie
Abstract

The prognosis of steroid-refractory acute graft-versus-host disease (aGVHD) remains poor and better treatments are urgently needed. Multipotent mesenchymal stromal cell (MSC)-based therapy emerged as a promising approach but response rates were highly variable across studies. We conducted a multicenter prospective study assessing the efficacy of 1-2 infusion(s) of cryopreserved, third-party donor bone marrow-derived MSCs for treating grade II-IV steroid-refractory or -dependent aGVHD in a series of 33 patients. MSCs were produced centrally and distributed to 8 hospitals throughout Belgium to be infused in 2 consecutive cohorts of patients receiving 1-2 or 3-4 × 106 MSCs/kg per dose, respectively. All patients received MSCs as the first rescue therapy after corticosteroids, with the exception for one patient who received prior treatment with mycophenolate mofetil (that was still ongoing by the time of MSC therapy). In these conditions, MSC therapy resulted in at least a partial response in 13 patients (40.6%) at day 30 and in 15 patients (46%) within 90 days after first MSC infusion. The corresponding complete response rates were 21.6% (7 patients) and 30% (10 patients), respectively. Only 5 patients achieved a sustained complete response, lasting for at least 1 month. The 1-year overall survival was 18.2% (95% CI: 8.82-37.5%). Higher response and survival rates were observed among patients receiving 3-4 × 106 MSCs/kg for first infusion, as compared with patients receiving 1-2 × 106 MSCs/ kg. Response and survival with MSC therapy for SR/SD-aGVHD remains to be optimized., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2018

39. A New Method for Estimating Treatment-Related Mortality for Older Patients

Author

de Wreede, Liesbeth C., primary, Schetelig, Johannes, additional, Putter, Hein, additional, van Biezen, Anja, additional, Koster, Linda, additional, Iacobelli, Simona, additional, Perme, Maja Pohar, additional, van Gelder, Michel, additional, Scheid, Christof, additional, Schoenland, Stefan, additional, Hayden, Patrick John, additional, Yakoub-Agha, Ibrahim, additional, Robin, Marie, additional, and Kroeger, Nicolaus, additional

Published
2019
Full Text
View/download PDF

40. Central Nervous System Localisation of Multiple Myeloma

Author

van der Poel, Marjolein, van Gelder, Michel, Abdul Hamid, Myrurgia A., Smulders, Martijn, de Coninck, Aniek, MUMC+: MA Hematologie (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Promovendi ODB, Interne Geneeskunde, RS: GROW - R4 - Reproductive and Perinatal Medicine, MUMC+: DA Pat Pathologie (9), MUMC+: MA Med Staf Artsass Interne Geneeskunde (9), and MUMC+: MA Alg Ond Onderz Cardiologie (9)

Published
2017

41. Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia

Author

Schetelig, Johannes, primary, de Wreede, Liesbeth C., additional, van Gelder, Michel, additional, Koster, Linda, additional, Finke, Jürgen, additional, Niederwieser, Dietger, additional, Beelen, Dietrich, additional, Mufti, G. J., additional, Platzbecker, Uwe, additional, Ganser, Arnold, additional, Heidenreich, Silke, additional, Maertens, Johan, additional, Socié, Gerard, additional, Brecht, Arne, additional, Stelljes, Matthias, additional, Kobbe, Guido, additional, Volin, Liisa, additional, Nagler, Arnon, additional, Vitek, Antonin, additional, Luft, Thomas, additional, Ljungman, Per, additional, Yakoub-Agha, Ibrahim, additional, Robin, Marie, additional, and Kröger, Nicolaus, additional

Published
2018
Full Text
View/download PDF

42. Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Author

d'Amore, Francesco, primary, Leppä, Sirpa, additional, Silva, Maria Gomes da, additional, Relander, Thomas, additional, Lauritzsen, Grete Fossum, additional, Brown, Peter De Nully, additional, Pezzutto, Antonio, additional, Doorduijn, Jeanette K., additional, Weidmann, Eckhart, additional, van Gelder, Michel, additional, Hoof, Achiel Van, additional, Christiansen, Ilse, additional, Fagerli, Unn Merete, additional, Hagberg, Hans, additional, Lugtenburg, P.J., additional, Walewski, Jan, additional, Wu, Ka Lung, additional, Demuynck, Hilde Maria, additional, Fijnheer, Rob, additional, Christensen, Jacob H., additional, Jankovská, Milada, additional, Josefsson, Pär L., additional, Kluin-Nelemans, Hanneke, additional, Mariz, Jose Mario, additional, Merup, Mats A., additional, Noesslinger, Thomas, additional, Van Den Neste, Eric, additional, Zijlstra, Josée M, additional, Hopfinger, Georg, additional, Prochazka, VIT, additional, Jantunen, Esa, additional, Boudova, Ludmila, additional, Cabecadas, Jose, additional, Chott, Andreas, additional, Delabie, Jan M.A., additional, de Leval, Laurence, additional, Diepstra, Arjan, additional, Karjalainen-Lindsberg, Marja-Liisa, additional, Noergaard, Peter, additional, Rosenwald, Andreas, additional, Rymkiewicz, Grzegorz, additional, Sundström, Christer, additional, Truemper, Lorenz, additional, Wulf, Gerald, additional, Chong, Lauren, additional, Bouska, Alyssa, additional, Smith, Lynette, additional, Gisselbrecht, Christian, additional, Ziepert, Marita, additional, Loeffler, Markus, additional, Liestol, Knut, additional, Steidl, Christian, additional, Gascoyne, Randy D., additional, Scott, David W., additional, Altmann, Bettina, additional, Iqbal, Javeed, additional, Chan, Wing C, additional, and Toldbod, Helle, additional

Published
2018
Full Text
View/download PDF

43. Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT)

Author

Schetelig, Johannes, de Wreede, Liesbeth C., Andersen, Niels S., Moreno, Carol, van Gelder, Michel, Vitek, Antonin, Karas, Michal, Michallet, Mauricette, Machaczka, Maciej, Gramatzki, Martin, Beelen, Dietrich, Finke, Jürgen, Delgado, Julio, Volin, Liisa, Passweg, Jakob, Dreger, Peter, Schaap, Nicolaas, Wagner, Eva, Henseler, Anja, van Biezen, Anja, Bornhäuser, Martin, Iacobelli, Simona, Putter, Hein, Schönland, Stefan O., Kröger, Nicolaus, Esteve, Jordi, Ljungman, Per, de Witte, Theo, Stelljes, Matthias, Sierra, Jorge, Socié, Gerard, Ganser, Arnold, Wulf, Gerhard G., Deconinck, Eric, Faber, Edgar, Feguex, Nathalie, Gedde-Dahl, Tobias, Kolbe, Karin, Chalandon, Yves, Krüger, William, Huynh, Anne, Bourhis, Jean Henri, Schouten, Harry, Ribera Santasusana, Josep M., Interne Geneeskunde, MUMC+: MA Hematologie (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, and Chalandon, Yves

Subjects
Oncology, Male, Transplantation Conditioning, Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2], Chronic lymphocytic leukemia, Medizin, QUALITY MANAGEMENT-SYSTEM, Kaplan-Meier Estimate, risk factor analysis, GUIDELINES, Biochemistry, allogeneic stem cell transplantation, centre effects, chronic lymphocytic leukaemia, frailties, Transplantation Conditioning / methods, 0302 clinical medicine, Recurrence, Risk Factors, Leukemia, Lymphocytic, Chronic, B-Cell / mortality, Registries, Delivery of Health Care / statistics & numerical data, IBRUTINIB, ddc:616, 0303 health sciences, ALEMTUZUMAB, Hazard ratio, Hematopoietic Stem Cell Transplantation, Professional Practice, Hematology, Middle Aged, 3. Good health, Europe, 030220 oncology & carcinogenesis, ABT-199, Cohort, SURVIVAL, Alemtuzumab, Female, Europe / epidemiology, medicine.drug, Adult, medicine.medical_specialty, Allogeneic transplantation, Immunology, Lower risk, DIAGNOSIS, Settore MED/01 - Statistica Medica, 03 medical and health sciences, Leukemia, Lymphocytic, Chronic, B-Cell / therapy, Hematopoietic Stem Cell Transplantation / methods, Internal medicine, medicine, Humans, Karnofsky Performance Status, 030304 developmental biology, Aged, Retrospective Studies, business.industry, Proportional hazards model, CHRONIC LYMPHOCYTIC-LEUKEMIA, Retrospective cohort study, STEM-CELL TRANSPLANTATION, Cell Biology, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, Confidence interval, Surgery, Professional Practice / statistics & numerical data, Transplantation, business, Delivery of Health Care, 030215 immunology, RESPONSES
Abstract

Introduction:Even in the era of novel targeted therapies for the treatment of Chronic Lymphocytic Leukemia (CLL) patients, such as BTK, PI3K and BCL2 inhibitors, allogeneic hematopoietic stem cell transplantations (alloHCT) will remain an important treatment option for a subset of patients with very high risk CLL. The current study focused on the impact of center and procedure-related factors on outcomes after alloHCT, taking into account the impact of patient- and disease-related risk factors. Patients and Methods:Data of 684 CLL patients who received a first alloHCT between 2000 and 2011 were analyzed. Their data were collected as part of the EBMT CLL Data Quality Initiative. Outcomes of interest were Event-Free Survival (EFS) up to 5 years after transplantation and mortality in the first 100 days after alloHCT. Outcomes were analyzed by means of the Kaplan-Meier method and Cox proportional hazards models with a frailty (random effects) component to take into account unexplained center heterogeneity. The following factors describing center characteristics or the transplant procedure were analyzed: experience in alloHCT in general and, for CLL specifically, accreditation by the Joint Accreditation Committee-ISCT & EBMT (JACIE), Gross National Income (GNI)/capita based on purchasing power parity (PPP) (GNI/cap), donor type, donor-patient sex-match, type of conditioning, stem cell source and T-cell depletion (TCD). Results:Five-year EFS of the whole cohort was 37% (95% Confidence Interval, 33%-42%), Day-100 survival was 90% (88%-92%). Experience of the transplant center was measured by the number of all alloHCTs, and alloHCTs for patients with CLL respectively. The median total number of alloHCTs per center per year was 45 (range 0-169) and the median number of CLL alloHCTs was only 2 per center per year (range 0-19). Greater experience with transplantation of patients with CLL (Hazard Ratio (HR) 0.96 per additional transplant, p=0.002), JACIE accreditation (HR 0.7, p=0.045) and a higher GNI/cap (HR 0.4, 95% CI 0.2-0.96, p=0.04) showed a protective impact on 5-year EFS in the Cox model. In vivo TCD with alemtuzumab (HR 1.5 compared to no TCD, p=0.03) and a female donor for a male patient (HR 1.4 compared to a male donor for a male patient, p=0.02) were the only procedure-related factors significantly associated with EFS. Event-Free Survival after in vivo TCD with Anti-Thymocyte-Globulin or after ex vivo TCD was comparable to EFS without TCD (HR 0.9, 0.7-1.3, p=0.6; HR 0.9, 0.5-1.6, p=0.8). Non-myeloablative conditioning did not have a negative impact on 5-year EFS, and exposed patients to a lower risk of non-relapse mortality. Measured and unmeasured center characteristics did not have a significant impact on 100-day mortality. Even when correcting for patient-, procedure- and center-related characteristics, there was still significant variation in center outcome, expressed by center-specific HRs derived from the frailty models, ranging from 0.6 to 1.2. Their impact is illustrated in a model-based plot for EFS (see Figure) which shows outcomes for three reference patients with the same characteristics who would be transplanted in three centers with the same measured characteristics but with the highest, average and lowest HRs in the dataset. These unexplained center effects likely represent a mixture of differences which could apply to the location of the transplant center, unmeasured characteristics of the patient population transplanted at this center, selection criteria which were not reported and factors determining the success of the transplant procedure which might differ between centers. Conclusion: We have confirmed that both center- and procedure-related factors have a significant impact on the EFS of patients with CLL undergoing alloHCT. Our results may help to interpret outcomes of single or multicenter studies better. Since non-myeloablative conditioning did not have a negative impact on EFS and exposed patients to a lower risk of non-relapse mortality, this approach should be favored for future alloHCT for CLL. Probability of Event-Free Survival up to Five Years Post-HCT for three Reference Patients Contribution: J.S. designed the research and wrote the paper. L.C.d.W conducted the statistical analysis and produced the figure. Figure Figure. Disclosures Schetelig: Sanofi: Honoraria. Gramatzki:Janssen: Other: Travel/Accommodation/Expenses, Research Funding. Dreger:Gilead: Consultancy; Gilead: Speakers Bureau; Janssen: Consultancy; Novartis: Speakers Bureau; Novartis: Consultancy; Roche: Consultancy.

Published
2017

44. Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia

Author

Kater, Arnon P., primary, van Oers, Marinus H.J., additional, van Norden, Yvette, additional, van der Straten, Lina, additional, Driessen, Julia, additional, Posthuma, Ward F.M., additional, Schipperus, Martin, additional, Chamuleau, Martine E.D., additional, Nijland, Marcel, additional, Doorduijn, Jeanette K., additional, Van Gelder, Michel, additional, Hoogendoorn, Mels, additional, De Croon, Francien, additional, Wittebol, Shulamiet, additional, Kerst, J. Martijn, additional, Marijt, Erik W.A., additional, Raymakers, Reinier A.P., additional, Schaafsma, Martijn R., additional, Dobber, Johan A., additional, Kersting, Sabina, additional, and Levin, Mark-David, additional

Published
2018
Full Text
View/download PDF

45. Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graft-versus-host disease: a multicenter prospective study

Author

Servais, Sophie, primary, Baron, Frédéric, additional, Lechanteur, Chantal, additional, Seidel, Laurence, additional, Selleslag, Dominik, additional, Maertens, Johan, additional, Baudoux, Etienne, additional, Zachee, Pierre, additional, Van Gelder, Michel, additional, Noens, Lucien, additional, Kerre, Tessa, additional, Lewalle, Philippe, additional, Schroyens, Wilfried, additional, Ory, Aurélie, additional, and Beguin, Yves, additional

Published
2018
Full Text
View/download PDF

47. Ibrutinib for Bridging to Allogeneic Hematopoietic Stem Cell Transplantation (alloHCT) in Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) Is Safe and Effective: First Results of a Survey By the Chronic Malignancy and the Lymphoma Working Parties of the EBMT

Author

Dreger, Peter, primary, Michallet, Mauricette, additional, Hoek, Jennifer, additional, Boumendil, Ariane, additional, Sobh, Mohamad, additional, Muller, Lutz, additional, Vandenberghe, Elisabeth A., additional, Scortechini, Ilaria, additional, Andersen, Niels S., additional, Finke, Jurgen, additional, Russo, Domenico, additional, Passweg, Jakob R, additional, Schoemans, Helene, additional, Durakovic, Nadira, additional, Labussiere, Helene, additional, Berg, Tobias, additional, Niederwieser, Dietger, additional, Bethge, Wolfgang, additional, Mordini, Nicola, additional, van Gelder, Michel, additional, Schaap, Nicolaas PM, additional, Kroger, Nicolaus, additional, Montoto, Silvia, additional, and Schetelig, Johannes, additional

Published
2016
Full Text
View/download PDF

48. Outcomes of Mismatched Related Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Author

van Gorkom, Gwendolyn, primary, van Gelder, Michel, additional, Ziagkos, Dimitris, additional, Blok, Henric-Jan, additional, van Lint, Maria Teresa, additional, Koc, Yener, additional, Ciceri, Fabio, additional, Beelen, Dietrich W., additional, Chevallier, Patrice, additional, Selleslag, Dominik, additional, Blaise, Didier, additional, Foà, Roberto, additional, Corradini, Paolo, additional, Castagna, Luca, additional, Moreno, Carol, additional, Solano, Carlos, additional, Müller, Lutz P., additional, Tischer, Johanna, additional, Hilgendorf, Inken, additional, Hallek, Michael, additional, Bittenbring, Joerg Thomas, additional, Theobald, Matthias, additional, Schetelig, Johannes, additional, and Kröger, Nicolaus, additional

Published
2016
Full Text
View/download PDF

49. Identification of Baseline Characteristics That Predict Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Chronic Lymphocytic Leukemia Patients - a Retrospective Analysis from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

Author

van Gelder, Michel, primary, Ziagkos, Dimitris, additional, de Wreede, Liesbeth C, additional, van Biezen, Anja, additional, Dreger, Peter, additional, Gramatzki, Martin, additional, Stelljes, Matthias, additional, Smedegaard Andersen, Niels, additional, Schaap, Nicolaas PM, additional, Vitek, Antonin, additional, Beelen, Dietrich, additional, Volin, Liisa, additional, Finke, Jürgen, additional, Passweg, Jakob R, additional, Ganser, Arnold, additional, Machaczka, Maciej J, additional, Delgado, Julio, additional, Krüger, William, additional, Faber, Edgar, additional, Socie, Gerard, additional, Jindra, Pavel, additional, Afanasyev, Boris V, additional, Theobald, Matthias, additional, Chalandon, Yves, additional, Henseler, Anja, additional, Schoenland, Stefan O., additional, Nicolaus, Kroger, additional, and Schetelig, Johannes, additional

Published
2016
Full Text
View/download PDF

50. Salvage Use of Ibrutinib after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) for B Cell Malignancies: A Study of the French Cooperative Group for CLL, the French Soceity for Blood and Marrow Transplantation (SFGM-TC), and the European Society for Blood and Marrow Transplantation (EBMT) Chronic Malignancy and Lymphoma Working Parties

Author

Michallet, Mauricette, primary, Dreger, Peter, additional, Sobh, Mohamad, additional, Hoek, Jennifer, additional, Boumendil, Ariane, additional, Muller, Lutz, additional, Corradini, Paolo, additional, Bethge, Wolfgang, additional, Russo, Domenico, additional, Durakovic, Nadira, additional, van Gelder, Michel, additional, Schaap, Nicolaas PM, additional, Kroger, Nicolaus, additional, and Schetelig, Johannes, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results